Effectiveness of monovalent rotavirus vaccine against hospitalization with acute rotavirus gastroenteritis in Kenyan children. Khagayi, S., Omore, R., Otieno, G. P., Ogwel, B., Ochieng, J. B., Juma, J., Apondi, E., Bigogo, G., Onyango, C., Ngama, M., Njeru, R., Owor, B. E., Mwanga, M. J., Addo, Y., Tabu, C., Amwayi, A., Mwenda, J. M., Tate, J. E., Parashar, U. D., Breiman, R. F., Nokes, D. J., & Verani, J. R. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America, July, 2019. doi abstract bibtex BACKGROUND: Rotavirus remains a leading cause of diarrheal illness and death among children worldwide. Data on rotavirus vaccine effectiveness in sub-Saharan Africa are limited. Kenya introduced monovalent rotavirus vaccine (RV1) in July 2014. We assessed RV1 effectiveness against rotavirus-associated hospitalization in Kenyan children. METHODS: Between July-2014 and December-2017, we conducted surveillance for acute gastroenteritis (AGE) in three hospitals across Kenya. We analysed data from children age-eligible for ≥1 RV1 dose, with stool tested for rotavirus and confirmed vaccination history. We compared RV1 coverage among those who tested rotavirus-positive (cases) versus rotavirus-negative (controls) using multivariable logistic regression; effectiveness was 1-adjusted odds ratio for vaccination x100%. RESULTS: Among 677 eligible children, 110 (16%) were rotavirus-positive. Vaccination data were available for 91 (83%) cases; 51 (56%) had received 2 RV1 doses and 33 (36%) 0 doses. Among 567 controls, 418 (74%) had vaccination data; 308 (74%) had 2 doses and 69 (16%) 0 doses. Overall 2-dose effectiveness was 64% (95% confidence interval [CI]: 35-80%); for children aged \textless12 months 67% (95%CI: 30-84%) and children aged ≥12 months 72% (95%CI: 10-91%). Significant effectiveness was seen in children with normal weight-for-age (84% [95%CI: 62-93%]), length/height-for-age (75% [95%CI: 48-88%]) and weight-for-length/height (84% [95%CI: 64-93%]); however, no protection was found among underweight, stunted nor wasted children. CONCLUSIONS: RV1 in the routine Kenyan immunization program provides significant protection against rotavirus AGE hospitalization. Protection was sustained beyond infancy. Malnutrition appears to diminish vaccine effectiveness. Efforts to improve rotavirus vaccine uptake and nutritional status are important to maximize vaccine benefit.
@article{khagayi_effectiveness_2019,
title = {Effectiveness of monovalent rotavirus vaccine against hospitalization with acute rotavirus gastroenteritis in {Kenyan} children},
issn = {1537-6591},
doi = {10.1093/cid/ciz664},
abstract = {BACKGROUND: Rotavirus remains a leading cause of diarrheal illness and death among children worldwide. Data on rotavirus vaccine effectiveness in sub-Saharan Africa are limited. Kenya introduced monovalent rotavirus vaccine (RV1) in July 2014. We assessed RV1 effectiveness against rotavirus-associated hospitalization in Kenyan children.
METHODS: Between July-2014 and December-2017, we conducted surveillance for acute gastroenteritis (AGE) in three hospitals across Kenya. We analysed data from children age-eligible for ≥1 RV1 dose, with stool tested for rotavirus and confirmed vaccination history. We compared RV1 coverage among those who tested rotavirus-positive (cases) versus rotavirus-negative (controls) using multivariable logistic regression; effectiveness was 1-adjusted odds ratio for vaccination x100\%.
RESULTS: Among 677 eligible children, 110 (16\%) were rotavirus-positive. Vaccination data were available for 91 (83\%) cases; 51 (56\%) had received 2 RV1 doses and 33 (36\%) 0 doses. Among 567 controls, 418 (74\%) had vaccination data; 308 (74\%) had 2 doses and 69 (16\%) 0 doses. Overall 2-dose effectiveness was 64\% (95\% confidence interval [CI]: 35-80\%); for children aged {\textless}12 months 67\% (95\%CI: 30-84\%) and children aged ≥12 months 72\% (95\%CI: 10-91\%). Significant effectiveness was seen in children with normal weight-for-age (84\% [95\%CI: 62-93\%]), length/height-for-age (75\% [95\%CI: 48-88\%]) and weight-for-length/height (84\% [95\%CI: 64-93\%]); however, no protection was found among underweight, stunted nor wasted children.
CONCLUSIONS: RV1 in the routine Kenyan immunization program provides significant protection against rotavirus AGE hospitalization. Protection was sustained beyond infancy. Malnutrition appears to diminish vaccine effectiveness. Efforts to improve rotavirus vaccine uptake and nutritional status are important to maximize vaccine benefit.},
language = {eng},
journal = {Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America},
author = {Khagayi, Sammy and Omore, Richard and Otieno, Grieven P. and Ogwel, Billy and Ochieng, John B. and Juma, Jane and Apondi, Evans and Bigogo, Godfrey and Onyango, Clayton and Ngama, Mwanajuma and Njeru, Regina and Owor, Betty E. and Mwanga, Mike J. and Addo, Yaw and Tabu, Collins and Amwayi, Anyangu and Mwenda, Jason M. and Tate, Jacqueline E. and Parashar, Umesh D. and Breiman, Robert F. and Nokes, D. James and Verani, Jennifer R.},
month = jul,
year = {2019},
pmid = {31326980},
}
Downloads: 0
{"_id":"tRbR4o2YXnyqGbfZW","bibbaseid":"khagayi-omore-otieno-ogwel-ochieng-juma-apondi-bigogo-etal-effectivenessofmonovalentrotavirusvaccineagainsthospitalizationwithacuterotavirusgastroenteritisinkenyanchildren-2019","author_short":["Khagayi, S.","Omore, R.","Otieno, G. P.","Ogwel, B.","Ochieng, J. B.","Juma, J.","Apondi, E.","Bigogo, G.","Onyango, C.","Ngama, M.","Njeru, R.","Owor, B. E.","Mwanga, M. J.","Addo, Y.","Tabu, C.","Amwayi, A.","Mwenda, J. M.","Tate, J. E.","Parashar, U. D.","Breiman, R. F.","Nokes, D. J.","Verani, J. R."],"bibdata":{"bibtype":"article","type":"article","title":"Effectiveness of monovalent rotavirus vaccine against hospitalization with acute rotavirus gastroenteritis in Kenyan children","issn":"1537-6591","doi":"10.1093/cid/ciz664","abstract":"BACKGROUND: Rotavirus remains a leading cause of diarrheal illness and death among children worldwide. Data on rotavirus vaccine effectiveness in sub-Saharan Africa are limited. Kenya introduced monovalent rotavirus vaccine (RV1) in July 2014. We assessed RV1 effectiveness against rotavirus-associated hospitalization in Kenyan children. METHODS: Between July-2014 and December-2017, we conducted surveillance for acute gastroenteritis (AGE) in three hospitals across Kenya. We analysed data from children age-eligible for ≥1 RV1 dose, with stool tested for rotavirus and confirmed vaccination history. We compared RV1 coverage among those who tested rotavirus-positive (cases) versus rotavirus-negative (controls) using multivariable logistic regression; effectiveness was 1-adjusted odds ratio for vaccination x100%. RESULTS: Among 677 eligible children, 110 (16%) were rotavirus-positive. Vaccination data were available for 91 (83%) cases; 51 (56%) had received 2 RV1 doses and 33 (36%) 0 doses. Among 567 controls, 418 (74%) had vaccination data; 308 (74%) had 2 doses and 69 (16%) 0 doses. Overall 2-dose effectiveness was 64% (95% confidence interval [CI]: 35-80%); for children aged \\textless12 months 67% (95%CI: 30-84%) and children aged ≥12 months 72% (95%CI: 10-91%). Significant effectiveness was seen in children with normal weight-for-age (84% [95%CI: 62-93%]), length/height-for-age (75% [95%CI: 48-88%]) and weight-for-length/height (84% [95%CI: 64-93%]); however, no protection was found among underweight, stunted nor wasted children. CONCLUSIONS: RV1 in the routine Kenyan immunization program provides significant protection against rotavirus AGE hospitalization. Protection was sustained beyond infancy. Malnutrition appears to diminish vaccine effectiveness. Efforts to improve rotavirus vaccine uptake and nutritional status are important to maximize vaccine benefit.","language":"eng","journal":"Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America","author":[{"propositions":[],"lastnames":["Khagayi"],"firstnames":["Sammy"],"suffixes":[]},{"propositions":[],"lastnames":["Omore"],"firstnames":["Richard"],"suffixes":[]},{"propositions":[],"lastnames":["Otieno"],"firstnames":["Grieven","P."],"suffixes":[]},{"propositions":[],"lastnames":["Ogwel"],"firstnames":["Billy"],"suffixes":[]},{"propositions":[],"lastnames":["Ochieng"],"firstnames":["John","B."],"suffixes":[]},{"propositions":[],"lastnames":["Juma"],"firstnames":["Jane"],"suffixes":[]},{"propositions":[],"lastnames":["Apondi"],"firstnames":["Evans"],"suffixes":[]},{"propositions":[],"lastnames":["Bigogo"],"firstnames":["Godfrey"],"suffixes":[]},{"propositions":[],"lastnames":["Onyango"],"firstnames":["Clayton"],"suffixes":[]},{"propositions":[],"lastnames":["Ngama"],"firstnames":["Mwanajuma"],"suffixes":[]},{"propositions":[],"lastnames":["Njeru"],"firstnames":["Regina"],"suffixes":[]},{"propositions":[],"lastnames":["Owor"],"firstnames":["Betty","E."],"suffixes":[]},{"propositions":[],"lastnames":["Mwanga"],"firstnames":["Mike","J."],"suffixes":[]},{"propositions":[],"lastnames":["Addo"],"firstnames":["Yaw"],"suffixes":[]},{"propositions":[],"lastnames":["Tabu"],"firstnames":["Collins"],"suffixes":[]},{"propositions":[],"lastnames":["Amwayi"],"firstnames":["Anyangu"],"suffixes":[]},{"propositions":[],"lastnames":["Mwenda"],"firstnames":["Jason","M."],"suffixes":[]},{"propositions":[],"lastnames":["Tate"],"firstnames":["Jacqueline","E."],"suffixes":[]},{"propositions":[],"lastnames":["Parashar"],"firstnames":["Umesh","D."],"suffixes":[]},{"propositions":[],"lastnames":["Breiman"],"firstnames":["Robert","F."],"suffixes":[]},{"propositions":[],"lastnames":["Nokes"],"firstnames":["D.","James"],"suffixes":[]},{"propositions":[],"lastnames":["Verani"],"firstnames":["Jennifer","R."],"suffixes":[]}],"month":"July","year":"2019","pmid":"31326980","bibtex":"@article{khagayi_effectiveness_2019,\n\ttitle = {Effectiveness of monovalent rotavirus vaccine against hospitalization with acute rotavirus gastroenteritis in {Kenyan} children},\n\tissn = {1537-6591},\n\tdoi = {10.1093/cid/ciz664},\n\tabstract = {BACKGROUND: Rotavirus remains a leading cause of diarrheal illness and death among children worldwide. Data on rotavirus vaccine effectiveness in sub-Saharan Africa are limited. Kenya introduced monovalent rotavirus vaccine (RV1) in July 2014. We assessed RV1 effectiveness against rotavirus-associated hospitalization in Kenyan children.\nMETHODS: Between July-2014 and December-2017, we conducted surveillance for acute gastroenteritis (AGE) in three hospitals across Kenya. We analysed data from children age-eligible for ≥1 RV1 dose, with stool tested for rotavirus and confirmed vaccination history. We compared RV1 coverage among those who tested rotavirus-positive (cases) versus rotavirus-negative (controls) using multivariable logistic regression; effectiveness was 1-adjusted odds ratio for vaccination x100\\%.\nRESULTS: Among 677 eligible children, 110 (16\\%) were rotavirus-positive. Vaccination data were available for 91 (83\\%) cases; 51 (56\\%) had received 2 RV1 doses and 33 (36\\%) 0 doses. Among 567 controls, 418 (74\\%) had vaccination data; 308 (74\\%) had 2 doses and 69 (16\\%) 0 doses. Overall 2-dose effectiveness was 64\\% (95\\% confidence interval [CI]: 35-80\\%); for children aged {\\textless}12 months 67\\% (95\\%CI: 30-84\\%) and children aged ≥12 months 72\\% (95\\%CI: 10-91\\%). Significant effectiveness was seen in children with normal weight-for-age (84\\% [95\\%CI: 62-93\\%]), length/height-for-age (75\\% [95\\%CI: 48-88\\%]) and weight-for-length/height (84\\% [95\\%CI: 64-93\\%]); however, no protection was found among underweight, stunted nor wasted children.\nCONCLUSIONS: RV1 in the routine Kenyan immunization program provides significant protection against rotavirus AGE hospitalization. Protection was sustained beyond infancy. Malnutrition appears to diminish vaccine effectiveness. Efforts to improve rotavirus vaccine uptake and nutritional status are important to maximize vaccine benefit.},\n\tlanguage = {eng},\n\tjournal = {Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America},\n\tauthor = {Khagayi, Sammy and Omore, Richard and Otieno, Grieven P. and Ogwel, Billy and Ochieng, John B. and Juma, Jane and Apondi, Evans and Bigogo, Godfrey and Onyango, Clayton and Ngama, Mwanajuma and Njeru, Regina and Owor, Betty E. and Mwanga, Mike J. and Addo, Yaw and Tabu, Collins and Amwayi, Anyangu and Mwenda, Jason M. and Tate, Jacqueline E. and Parashar, Umesh D. and Breiman, Robert F. and Nokes, D. James and Verani, Jennifer R.},\n\tmonth = jul,\n\tyear = {2019},\n\tpmid = {31326980},\n}\n\n","author_short":["Khagayi, S.","Omore, R.","Otieno, G. P.","Ogwel, B.","Ochieng, J. B.","Juma, J.","Apondi, E.","Bigogo, G.","Onyango, C.","Ngama, M.","Njeru, R.","Owor, B. E.","Mwanga, M. J.","Addo, Y.","Tabu, C.","Amwayi, A.","Mwenda, J. M.","Tate, J. E.","Parashar, U. D.","Breiman, R. F.","Nokes, D. J.","Verani, J. R."],"key":"khagayi_effectiveness_2019","id":"khagayi_effectiveness_2019","bibbaseid":"khagayi-omore-otieno-ogwel-ochieng-juma-apondi-bigogo-etal-effectivenessofmonovalentrotavirusvaccineagainsthospitalizationwithacuterotavirusgastroenteritisinkenyanchildren-2019","role":"author","urls":{},"metadata":{"authorlinks":{}},"html":""},"bibtype":"article","biburl":"https://bibbase.org/zotero/robin.marlow","dataSources":["ix72eqAAMGCuupBaz"],"keywords":[],"search_terms":["effectiveness","monovalent","rotavirus","vaccine","against","hospitalization","acute","rotavirus","gastroenteritis","kenyan","children","khagayi","omore","otieno","ogwel","ochieng","juma","apondi","bigogo","onyango","ngama","njeru","owor","mwanga","addo","tabu","amwayi","mwenda","tate","parashar","breiman","nokes","verani"],"title":"Effectiveness of monovalent rotavirus vaccine against hospitalization with acute rotavirus gastroenteritis in Kenyan children","year":2019}